AER 1484164 is a market research program and patient support program, received on 30/Oct/2014 from a 
physician via company representative and concerns a patient of unspecified demographic who developed suffered 
progressive multifocal leukoencephalopathy while participated in(b) (6)
(b) (6)
Patient's medical history, concurrent illnesses, concomitant medications or past drugs were not reported.
On an unspecified date, patient started therapy with intravenous rituximab infusion (dose and frequency not 
reported) for rheumatoid arthritis. Later on, patient developed suffered progressive multifocal leukoencephalopathy.
At the time of this report, outcome of suffered progressive multifocal leukoencephalopathy was not reported and it 
was unknown whether therapy with rituximab was maintained or not.
Print Time: 24-MAY-2016 07:56 AM If a field is blank, there is no data for that field Page 551 of 570
FDA - Adverse Event Reporting System (FAERS) 
FOIA Case Report Information
The reporter assessed suffered progressive multifocal leukoencephalopathy as related with rituximab.
The company assessed suffered progressive multifocal leukoencephalopathy  as medical significant.
No further information was provided.